ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL HEART, LUNG, AND BLOOD INSTITUTE

Molecular Determinants of Atherosclerotic Cardiovascular Disease in Multi-ethnic Populations

Active
Institution
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX
Principal investigator
Bing Yu
Funding
$708K
Duration
2023–2027
Open portfolio

Moonbase score

Still being scored

Abstract

ABSTRACT Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of death worldwide. Understanding the process of atherosclerosis and its progression is essential to decrease ASCVD burden. Despite successful identification of genetic variants and clinical risk factors related to ASCVD over the last decade, the underlying mechanism - how genetic variants and human metabolism contribute to atherosclerosis remains unclear. Circulating metabolites, the ultimate products of gene and environment interaction, holds promise to link genetic variants, circulating metabolites to atherosclerosis. We previous work has shown that circulating metabolites involved in lipids and oxidation metabolism and their genetic determinants predict the onset of ASCVD. Few studies have examined the metabolic influence on atherosclerosis in multi-ethnic populations, and the effect of longitudinal metabolomic changes on atherosclerosis. Our overall objective is to identify circulating metabolite and its longitudinal change, along with the genetic determinants, contributing to atherosclerosis and ASCVD in middle and late life among multi-ethnic populations. We propose to conduct this project in six studies from the Trans-Omics for Precision Medicine (TOPMed) Program, including European, African and Hispanic Americans. We will leverage the unique resources from each study on whole genome sequencing (WGS) data, metabolome profiles, and atherosclerotic traits, and use TOPMed Cloud Computing as the computational engine. Our aims are: (1) to identify circulating metabolite and it change associated with ASCVD risk; (2) to determine circulating metabolite and it change associated subclinical atherosclerosis and its progression; and (3) to characterize genetic architecture of ASCVD metabolites and evaluate its association with ASCVD risk. Our team is uniquely positioned, given our expertise in ASCVD pathophysiology, metabolome profiling, genomics, biostatistics and bioinformatics. The results of this research will enable continued scientific progress toward an understanding of ASCVD etiology, with direct implications for prevention and potential therapies.

LOADING MOONBASE SCORE

NATIONAL HEART, LUNG, AND BLOOD INSTITUTER01Cardiovascular and Respiratory Diseases Study Section[CRD]atherosclerosistopmedatheroscleroticascvdcirculatingmulti-ethnicgenetic determinantsatherosclerotic cardiovascular

Questions for UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.